Similar Outcomes of Three Different Treatment Regimens Reported in Multiple Myeloma

Share this content:

the Cancer Therapy Advisor take:

Three salvage infusional chemotherapy regimens produced similar responses, survival, and adverse events in patients with multiple myeloma, according to an article published online in the journal Cancer.

In a single-institution study,  three salvage chemotherapy regimens were compared among 107 patients with recurrent multiple myeloma who were treated using one of three salvage chemotherapy regimens.

Fifty-two patients received dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) cohort; 22 received bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide (VTD-PACE) treatment group; and 33 patients received cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD).

There were some differences between groups. For example, patients treated with CVAD had a higher baseline creatinine (P<0.001) and those treated with VTD-PACE had greater prior use of infusional chemotherapy (P<0.001).

Regarding patient response, no significant differences were reported among the three groups (55% overall; P=0.18).

Similarly, no significantly different outcomes were reported for survival among the three groups: overall median progression-free survival of 4.5 months (95% CI: 3.6, 5.5 months; P=0.8) and a median overall survival of 8.5 months (95% CI: 6.1, 11 months; P=0.8). DCEP, VTD-PACE, and CVAD demonstrated similar clinical adverse events; however, it was noted that DCEP was suggested as having fewer events.

Sixty-two percent of patients with the intent to transplant were successfully bridged to transplant without further therapy (P=0.9).

Furthermore, the intent-to-transplant population had greater response outcomes (OR, 3.40; P=0.01), superior progression-free survival (HR, 0.28; P<0.001), and increased overall survival (HR, 0.19; P<0.001).

In patients with completely resected high-risk stage 3 melanoma, adjuvant ipilimumab significantly i
Three salvage infusional chemotherapy regimens produced similar responses, survival, and adverse events in patients with multiple myeloma.
Despite the impact of proteasome inhibitors and immunomodulatory agents, infusional chemotherapy regimens continue to be used for patients with multiple myeloma.
READ FULL ARTICLE From Wiley Online Library

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs